essential thrombocythemia
essential thrombocythemia
Explore linked clinical trials. Standard reference: MONDO:000502955 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-09 | NCT07441694 | |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 3 | 2026-10-08 | NCT07623200 | |
| MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Not stated | 2026-10-07 | NCT07863466 | |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-07 | NCT07849231 | |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06079879 | |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 2 | 2026-09-30 | NCT06661915 | |
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Not yet recruiting | Not applicable | 2026-09-29 | NCT07349134 | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, myeloproliferative neoplasm, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Phase 1 | 2026-09-28 | NCT05025488 | |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, acquired polycythemia vera, acute monocytic leukemia, acute myeloid leukemia, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, myeloproliferative neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 2 | 2026-09-17 | NCT04282187 | |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-08-27 | NCT06456346 | |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, thrombocytosis disease | Active, not recruiting | Phase 2 | 2026-08-13 | NCT02577926 | |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, myeloproliferative neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Not applicable | 2026-08-10 | NCT06361641 | |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Phase 1 | 2026-08-10 | NCT05936359 | |
| 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, central nervous system cancer, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, nervous system disorder, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Not stated | 2026-08-10 | NCT00935090 | |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-08-06 | NCT07008118 | |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, leukemia, myeloid leukemia, neoplasm, polycythemia, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-07-28 | NCT07527221 | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04285086 | |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Chronic Disease, Disease Attributes, Eosinophilia, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acquired polycythemia vera, acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cellular phase chronic idiopathic myelofibrosis, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, hypereosinophilic syndrome, leukemia, leukocyte disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, myeloid neoplasm, myeloproliferative neoplasm, myeloproliferative neoplasm, unclassifiable, neoplasm, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-16 | NCT03862157 | |
| Registry of Older Patients With Cancer | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Immunoglobulin Light-chain Amyloidosis, Infections, Leukemia, B-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute biphenotypic leukemia, acute myeloid leukemia, amyloidosis, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, intraocular lymphoma, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, mast cell leukemia, mastocytosis, metabolic disease, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, ocular cancer, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, prolymphocytic leukemia, proteostasis deficiencies, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Recruiting | Not stated | 2026-06-29 | NCT01137825 | |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acquired polycythemia vera, acute myeloid leukemia, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, chronic myelomonocytic leukemia, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, leukemia, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Phase 2 | 2026-06-23 | NCT03289910 | |
| A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 2 | 2026-06-16 | NCT06786234 | |
| CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Not yet recruiting | Not stated | 2026-06-12 | NCT07645755 | |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 1 / Phase 2 | 2026-06-03 | NCT07612280 | |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Bone Marrow Failure Disorders, Burkitt lymphoma, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, Herpesviridae infectious disease, Hodgkins lymphoma, Infections, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Lymphadenopathy, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Sezary syndrome, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, Waldenstrom macroglobulinemia, acquired polycythemia vera, acute myeloid leukemia, anaplastic large cell lymphoma, anemia, angioimmunoblastic T-cell lymphoma, aplastic anemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, diffuse large B-cell lymphoma, essential thrombocythemia, follicular lymphoma, graft versus host disease, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemolytic anemia, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, juvenile myelomonocytic leukemia, large-cell immunoblastic lymphoma, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, plasma cell neoplasm, precancerous condition, primary cutaneous T-cell non-Hodgkin lymphoma, primary myelofibrosis, thrombocytosis disease, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Phase 2 | 2026-06-02 | NCT00544115 | |
| Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis disease | Recruiting | Not stated | 2026-05-15 | NCT07590986 |